CN112137975A - Altrenogest tablet and dry preparation method thereof - Google Patents
Altrenogest tablet and dry preparation method thereof Download PDFInfo
- Publication number
- CN112137975A CN112137975A CN202011186378.7A CN202011186378A CN112137975A CN 112137975 A CN112137975 A CN 112137975A CN 202011186378 A CN202011186378 A CN 202011186378A CN 112137975 A CN112137975 A CN 112137975A
- Authority
- CN
- China
- Prior art keywords
- altrenogest
- tablet
- mixture
- diluent
- flavoring agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides an altrenogest tablet and a dry preparation method thereof, and relates to the technical field of veterinary drugs. The altrenogest tablet is prepared from 0.9-1.1% of altrenogest, 75.6-92.4% of diluent, 4.5-5.5% of sour agent and 9.0-11% of flavoring agent according to the weight ratio, and the dry preparation method of the altrenogest tablet comprises the following steps of S1, drying and crushing the altrenogest and the diluent respectively, sieving the altrenogest and the diluent through a 100-mesh sieve, mixing the obtained product uniformly, S2, sieving the sour agent and the flavoring agent through the 100-mesh sieve respectively, mixing the obtained product and the first mixture uniformly in sequence to obtain a second mixture, S3, drying the second mixture at 60 ℃ for 4 hours, directly tabletting to obtain an altrenogest tablet, analyzing and packaging the obtained product after the qualified analysis and detection. The taste of the sow is regulated by the sour agent and the flavoring agent, so that the sow can independently feed, and the labor intensity of workers can be reduced.
Description
Technical Field
The invention relates to the technical field of veterinary drugs, and particularly relates to an altrenogest tablet and a dry preparation method thereof.
Background
Altrenogest is an artificially synthesized steroid progestogen, and the administration route is oral. Altrenogest acts similarly to natural progesterone. During administration, the composition can inhibit pituitary gland to secrete gonadotropin, and prevent follicular development and estrus; after the administration, the pituitary recovers to secrete gonadotropin, and the development and the estrus of the follicles are promoted. When the medicine is stopped, the development degree of the follicles is consistent, and the secretion of gonadotropin is synchronously recovered, so that all animals can estrus at the same period after the medicine is stopped for 5-8 days.
Therefore, in order to facilitate the large-scale management of the pig farm, the altrenogest is used for the synchronous oestrus of the sows, the centralized management of the oestrus, parturition and weaning of the sows, namely the breeding cycle, can be realized by the technology, the labor intensity of workers in the pig farm is reduced, the spread of epidemic diseases, particularly African swine fever, can be reduced, and the biological safety measures of the pig farm are ensured to be put in place.
The preparation of the altrenogest in domestic and foreign veterinary markets at the present stage is an altrenogest oral solution, and the liquid medicine is orally taken and irrigated to the sow in a feeder mode during use.
Meanwhile, the altrenogest tablet is prepared by a dry method, and compared with the wet method, the altrenogest tablet is simpler and more convenient to operate and higher in production efficiency.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides an altrenogest tablet and a dry preparation method thereof, and solves the problems that the oral administration difficulty of the existing altrenogest oral solution is high, the emotion of a sow is influenced, and the sow oestrus is not facilitated.
(II) technical scheme
In order to achieve the purpose, the invention is realized by the following technical scheme: the altrenogest tablet is prepared with altrenogest 0.9-1.1 wt%, diluent 75.6-92.4 wt%, sour agent 4.5-5.5 wt% and corrective 9.0-11 wt%.
Preferably, the diluent comprises at least one of milk powder, starch, modified starch, dextrin, lactose, glucose, sucrose, non-dairy creamer, whey powder, albumen powder and microcrystalline cellulose.
Preferably, the sour agent comprises at least one of citric acid, lactic acid, tartaric acid, malic acid, gluconic acid and acetic acid.
Preferably, the flavoring agent comprises at least one of sucrose, glucose, aspartame, orange peel syrup, cherry syrup, licorice syrup, mannitol, sorbitol, stevioside, aspartame, maltitol, xylitol, and food grade essence.
Preferably, the altrenogest is a synthetic progestogen which may be administered orally.
Preferably, the dry preparation method of the altrenogest tablet comprises the following steps:
s1, drying and crushing altrenogest and a diluent respectively, then sieving the dried altrenogest and the crushed altrenogest through a 100-mesh sieve, and then uniformly mixing to obtain a first mixture;
s2, respectively sieving the sour agent and the flavoring agent through a 100-mesh sieve, and then sequentially and uniformly mixing the sour agent and the flavoring agent with the first mixture to obtain a second mixture;
and S3, drying the second mixture at 60 ℃ for 4 hours, directly tabletting to obtain plain tablets, and packaging into products after the plain tablets are analyzed and detected to be qualified.
Preferably, the tablet can be further processed into at least one of sugar-coated tablet, chewable tablet, dispersible tablet, sustained-release tablet, special-shaped tablet and effervescent tablet.
(III) advantageous effects
The invention provides an altrenogest tablet and a dry preparation method thereof. The method has the following beneficial effects:
1. according to the invention, a drug delivery mode of directly feeding the sows is adopted, and a feeder is not needed for hard-irrigation drug feeding, so that the labor intensity of workers in a pig farm is greatly reduced.
2. According to the invention, the favorable sour and sweet taste of the sow is adopted, and the sow can directly chew and swallow the tablet by directly placing the tablet at the mouth of the sow by a worker in a pig farm, so that the phenomena of nausea, vomiting and vomiting are avoided.
3. The invention has the advantages of various types of adopted auxiliary material production, low production cost and contribution to large-scale production.
4. The invention adopts a dry preparation method, and has simple production process and higher production efficiency.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The first embodiment is as follows:
the embodiment of the invention provides an altrenogest tablet which is prepared from 0.9% of altrenogest, 85.6% of diluent, 4.5% of sour agent and 9.0% of flavoring agent.
The diluent comprises at least one of milk powder, starch, modified starch, dextrin, lactose, glucose, sucrose, vegetable fat powder, whey powder, protein powder and microcrystalline cellulose, the sour agent comprises at least one of citric acid, lactic acid, tartaric acid, malic acid, gluconic acid and acetic acid, the flavoring agent comprises at least one of sucrose, glucose, aspartame, orange peel syrup, cherry syrup, licorice syrup, mannitol, sorbitol, stevioside, aspartame, maltitol, xylitol and food-grade essence, and the allylpregnensin is a synthetic progestational hormone capable of being orally taken.
A dry preparation method of altrenogest tablets comprises the following steps:
s1, drying and crushing altrenogest and a diluent respectively, then sieving the dried altrenogest and the crushed altrenogest through a 100-mesh sieve, and then uniformly mixing to obtain a first mixture;
s2, respectively sieving the sour agent and the flavoring agent through a 100-mesh sieve, and then sequentially and uniformly mixing the sour agent and the flavoring agent with the first mixture to obtain a second mixture;
and S3, drying the second mixture at 60 ℃ for 4 hours, directly tabletting to obtain plain tablets, and packaging into products after the plain tablets are analyzed and detected to be qualified.
The tablet can be further processed into at least one of sugar-coated tablet, chewable tablet, dispersible tablet, delayed release tablet, special-shaped tablet, and effervescent tablet.
The application method of the altrenogest tablets comprises the following specific steps: the replacement gilt is fed once a day, one tablet at a time, with the specification of the altrenogest tablet of 20mg as a dose, and is continuously used for 18 days.
Example two:
the embodiment of the invention provides an altrenogest tablet which is prepared from 0.95% of altrenogest, 84.8% of diluent, 4.75% of sour agent and 9.5% of flavoring agent.
The diluent comprises at least one of milk powder, starch, modified starch, dextrin, lactose, glucose, sucrose, vegetable fat powder, whey powder, protein powder and microcrystalline cellulose, the sour agent comprises at least one of citric acid, lactic acid, tartaric acid, malic acid, gluconic acid and acetic acid, the flavoring agent comprises at least one of sucrose, glucose, aspartame, orange peel syrup, cherry syrup, licorice syrup, mannitol, sorbitol, stevioside, aspartame, maltitol, xylitol and food-grade essence, and the allylpregnensin is a synthetic progestational hormone capable of being orally taken.
A dry preparation method of altrenogest tablets comprises the following steps:
s1, drying and crushing altrenogest and a diluent respectively, then sieving the dried altrenogest and the crushed altrenogest through a 100-mesh sieve, and then uniformly mixing to obtain a first mixture;
s2, respectively sieving the sour agent and the flavoring agent through a 100-mesh sieve, and then sequentially and uniformly mixing the sour agent and the flavoring agent with the first mixture to obtain a second mixture;
and S3, drying the second mixture at 60 ℃ for 4 hours, directly tabletting to obtain plain tablets, and packaging into products after the plain tablets are analyzed and detected to be qualified.
The tablet can be further processed into at least one of sugar-coated tablet, chewable tablet, dispersible tablet, delayed release tablet, special-shaped tablet, and effervescent tablet.
The application method of the altrenogest tablets comprises the following specific steps: the replacement gilt is fed once a day, one tablet at a time, with the specification of the altrenogest tablet of 20mg as a dose, and is continuously used for 18 days.
Example three:
the embodiment of the invention provides an altrenogest tablet which is prepared from 1.0% of altrenogest, 84.0% of diluent, 5.0% of sour agent and 10.0% of flavoring agent.
The diluent comprises at least one of milk powder, starch, modified starch, dextrin, lactose, glucose, sucrose, vegetable fat powder, whey powder, protein powder and microcrystalline cellulose, the sour agent comprises at least one of citric acid, lactic acid, tartaric acid, malic acid, gluconic acid and acetic acid, the flavoring agent comprises at least one of sucrose, glucose, aspartame, orange peel syrup, cherry syrup, licorice syrup, mannitol, sorbitol, stevioside, aspartame, maltitol, xylitol and food-grade essence, and the allylpregnensin is a synthetic progestational hormone capable of being orally taken.
A dry preparation method of altrenogest tablets comprises the following steps:
s1, drying and crushing altrenogest and a diluent respectively, then sieving the dried altrenogest and the crushed altrenogest through a 100-mesh sieve, and then uniformly mixing to obtain a first mixture;
s2, respectively sieving the sour agent and the flavoring agent through a 100-mesh sieve, and then sequentially and uniformly mixing the sour agent and the flavoring agent with the first mixture to obtain a second mixture;
and S3, drying the second mixture at 60 ℃ for 4 hours, directly tabletting to obtain plain tablets, and packaging into products after the plain tablets are analyzed and detected to be qualified.
The tablet can be further processed into at least one of sugar-coated tablet, chewable tablet, dispersible tablet, delayed release tablet, special-shaped tablet, and effervescent tablet.
The application method of the altrenogest tablets comprises the following specific steps: the replacement gilt is fed once a day, one tablet at a time, with the specification of the altrenogest tablet of 20mg as a dose, and is continuously used for 18 days.
Example four:
the embodiment of the invention provides an altrenogest tablet which is prepared from 1.05% of altrenogest, 83.2% of diluent, 5.25% of sour agent and 10.5% of flavoring agent.
The diluent comprises at least one of milk powder, starch, modified starch, dextrin, lactose, glucose, sucrose, vegetable fat powder, whey powder, protein powder and microcrystalline cellulose, the sour agent comprises at least one of citric acid, lactic acid, tartaric acid, malic acid, gluconic acid and acetic acid, the flavoring agent comprises at least one of sucrose, glucose, aspartame, orange peel syrup, cherry syrup, licorice syrup, mannitol, sorbitol, stevioside, aspartame, maltitol, xylitol and food-grade essence, and the allylpregnensin is a synthetic progestational hormone capable of being orally taken.
A dry preparation method of altrenogest tablets comprises the following steps:
s1, drying and crushing altrenogest and a diluent respectively, then sieving the dried altrenogest and the crushed altrenogest through a 100-mesh sieve, and then uniformly mixing to obtain a first mixture;
s2, respectively sieving the sour agent and the flavoring agent through a 100-mesh sieve, and then sequentially and uniformly mixing the sour agent and the flavoring agent with the first mixture to obtain a second mixture;
and S3, drying the second mixture at 60 ℃ for 4 hours, directly tabletting to obtain plain tablets, and packaging into products after the plain tablets are analyzed and detected to be qualified.
The tablet can be further processed into at least one of sugar-coated tablet, chewable tablet, dispersible tablet, delayed release tablet, special-shaped tablet, and effervescent tablet.
The application method of the altrenogest tablets comprises the following specific steps: the replacement gilt is fed once a day, one tablet at a time, with the specification of the altrenogest tablet of 20mg as a dose, and is continuously used for 18 days.
Example five:
the embodiment of the invention provides an altrenogest tablet which is prepared from 1.1% of altrenogest, 82.4% of diluent, 5.5% of sour agent and 11% of flavoring agent.
The diluent comprises at least one of milk powder, starch, modified starch, dextrin, lactose, glucose, sucrose, vegetable fat powder, whey powder, protein powder and microcrystalline cellulose, the sour agent comprises at least one of citric acid, lactic acid, tartaric acid, malic acid, gluconic acid and acetic acid, the flavoring agent comprises at least one of sucrose, glucose, aspartame, orange peel syrup, cherry syrup, licorice syrup, mannitol, sorbitol, stevioside, aspartame, maltitol, xylitol and food-grade essence, and the allylpregnensin is a synthetic progestational hormone capable of being orally taken.
A dry preparation method of altrenogest tablets comprises the following steps:
s1, drying and crushing altrenogest and a diluent respectively, then sieving the dried altrenogest and the crushed altrenogest through a 100-mesh sieve, and then uniformly mixing to obtain a first mixture;
s2, respectively sieving the sour agent and the flavoring agent through a 100-mesh sieve, and then sequentially and uniformly mixing the sour agent and the flavoring agent with the first mixture to obtain a second mixture;
and S3, drying the second mixture at 60 ℃ for 4 hours, directly tabletting to obtain plain tablets, and packaging into products after the plain tablets are analyzed and detected to be qualified.
The tablet can be further processed into at least one of sugar-coated tablet, chewable tablet, dispersible tablet, delayed release tablet, special-shaped tablet, and effervescent tablet.
The application method of the altrenogest tablets comprises the following specific steps: the replacement gilt is fed once a day, one tablet at a time, with the specification of the altrenogest tablet of 20mg as a dose, and is continuously used for 18 days.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (7)
1. The altrenogest tablet is characterized by being prepared from 0.9-1.1% of altrenogest, 75.6-92.4% of diluent, 4.5-5.5% of sour agent and 9.0-11% of flavoring agent.
2. The altrenogest tablet of claim 1, wherein: the diluent comprises at least one of milk powder, starch, modified starch, dextrin, lactose, glucose, sucrose, non-dairy creamer, whey powder, protein powder and microcrystalline cellulose.
3. The altrenogest tablet of claim 1, wherein: the sour agent comprises at least one of citric acid, lactic acid, tartaric acid, malic acid, gluconic acid and acetic acid.
4. The altrenogest tablet of claim 1, wherein: the correctant comprises at least one of sucrose, glucose, aspartame, orange peel syrup, cherry syrup, Glycyrrhrizae radix syrup, mannitol, sorbitol, stevioside, aspartame, maltitol, xylitol, and food grade essence.
5. The altrenogest tablet of claim 1, wherein: the altrenogest is a synthetic progestogen that can be administered orally.
6. The dry preparation method of altrenogest tablet as claimed in claim 1, characterized by comprising the following steps:
s1, drying and crushing altrenogest and a diluent respectively, then sieving the dried altrenogest and the crushed altrenogest through a 100-mesh sieve, and then uniformly mixing to obtain a first mixture;
s2, respectively sieving the sour agent and the flavoring agent through a 100-mesh sieve, and then sequentially and uniformly mixing the sour agent and the flavoring agent with the first mixture to obtain a second mixture;
and S3, drying the second mixture at 60 ℃ for 4 hours, directly tabletting to obtain plain tablets, and packaging into products after the plain tablets are analyzed and detected to be qualified.
7. The altrenogest tablet and the dry preparation method thereof as claimed in claim 6, characterized in that: the tablet can be further processed into at least one of sugar-coated tablet, chewable tablet, dispersible tablet, sustained release tablet, special-shaped tablet, and effervescent tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011186378.7A CN112137975A (en) | 2020-10-30 | 2020-10-30 | Altrenogest tablet and dry preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011186378.7A CN112137975A (en) | 2020-10-30 | 2020-10-30 | Altrenogest tablet and dry preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112137975A true CN112137975A (en) | 2020-12-29 |
Family
ID=73953743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011186378.7A Pending CN112137975A (en) | 2020-10-30 | 2020-10-30 | Altrenogest tablet and dry preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112137975A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112587490A (en) * | 2020-12-22 | 2021-04-02 | 宁波第二激素厂 | Alsopreglin tablet and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120058171A1 (en) * | 2009-03-17 | 2012-03-08 | Wouter De Graaff | Zoo-technical drug delivery device |
| CN108042485A (en) * | 2017-11-08 | 2018-05-18 | 宁波三生生物科技有限公司 | A kind of Altrenogest preparation and preparation method thereof |
| CN108969496A (en) * | 2018-09-07 | 2018-12-11 | 江苏恒丰强生物技术有限公司 | A kind of pet benazepril hydrochloride chewable tablets and preparation method thereof |
| CN109464400A (en) * | 2018-12-29 | 2019-03-15 | 佛山市南海东方澳龙制药有限公司 | Altrenogest solid pharmaceutical preparation and its preparation method and application |
-
2020
- 2020-10-30 CN CN202011186378.7A patent/CN112137975A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120058171A1 (en) * | 2009-03-17 | 2012-03-08 | Wouter De Graaff | Zoo-technical drug delivery device |
| CN108042485A (en) * | 2017-11-08 | 2018-05-18 | 宁波三生生物科技有限公司 | A kind of Altrenogest preparation and preparation method thereof |
| CN108969496A (en) * | 2018-09-07 | 2018-12-11 | 江苏恒丰强生物技术有限公司 | A kind of pet benazepril hydrochloride chewable tablets and preparation method thereof |
| CN109464400A (en) * | 2018-12-29 | 2019-03-15 | 佛山市南海东方澳龙制药有限公司 | Altrenogest solid pharmaceutical preparation and its preparation method and application |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112587490A (en) * | 2020-12-22 | 2021-04-02 | 宁波第二激素厂 | Alsopreglin tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW391880B (en) | An oral soluble type compression moulding and its preparation | |
| US7544376B2 (en) | Methods and compositions for increasing milk production in animals | |
| EP3251523B1 (en) | Method for preparing granulated creep feed | |
| BR122013009981A2 (en) | composition to synchronize insemination time | |
| WO2020262325A1 (en) | Anti-aging agent for females | |
| CN103141713A (en) | Compound feed for pregnant pig and preparation method thereof | |
| CN109464400A (en) | Altrenogest solid pharmaceutical preparation and its preparation method and application | |
| CN108042485B (en) | A kind of Altrenogest preparation and preparation method thereof | |
| CN112137975A (en) | Altrenogest tablet and dry preparation method thereof | |
| Gardón et al. | Synchronization protocols in Spanish Merino sheep: reduction in time to estrus by the addition of eCG to a progesterone-based estrus synchronization protocol | |
| US8084440B2 (en) | Method for improving the fertility of animals | |
| CN105850871A (en) | Breeding method for increasing Boer goat lambing rate | |
| GIROUD | Malformations embryonnaires d'origine carentielle | |
| CN104739816B (en) | Bad Portugal's zinc medical composition and its use including chiral photo-isomerisation compound | |
| KR101067028B1 (en) | Composition for preventing and treating menopausal syndrome in women containing wild herbs extract | |
| CN104664168B (en) | A kind of piglet specific complex vitamin microemulsion preparation and its preparation method and application | |
| CN107028005B (en) | Preparation method of energy bar for perinatal sows | |
| Baldwin et al. | Rumen-protected methionine for lactation, wool and growth in sheep | |
| CN112641737A (en) | Preparation method of altrenogest chewable tablets | |
| CN115569129A (en) | Carbazoline calcium solid preparation and preparation method thereof | |
| US20150351428A1 (en) | Methods and compositions for orally dosing postnatal swine | |
| US20230091429A1 (en) | Composition for enhancing chances of conception and female sex ratio in bovines | |
| WO2011045800A1 (en) | Herbal compositions for inducing fertility in cattle | |
| CN110935007A (en) | Linaclotide compound composition, preparation, application and preparation method thereof | |
| Kumar et al. | Pre-and-postpartum managemental intervention through herbal feed supplement (Asparagus racemosus) and its effect on production and reproduction performance during supplementation and post-supplementation period in crossbred cows |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201229 |
|
| RJ01 | Rejection of invention patent application after publication |